{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T12:47:37Z","timestamp":1786366057273,"version":"build-2736575974"},"reference-count":124,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2026,1,3]],"date-time":"2026-01-03T00:00:00Z","timestamp":1767398400000},"content-version":"vor","delay-in-days":885,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2023,8,2]],"date-time":"2023-08-02T00:00:00Z","timestamp":1690934400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Boehringer Ingelheim Middle East & North Africa"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Although epidemiological data on heart failure (HF) with preserved ejection fraction (HFpEF) are scarce in the Middle East, North Africa and Turkey (MENAT) region, Lancet Global Burden of Disease estimated the prevalence of HF in the MENAT region in 2019 to be 0.78%, versus 0.71% globally. There is also a high incidence of HFpEF risk factors and co-morbidities in the region, including coronary artery disease, diabetes, obesity, hypertension, anaemia and chronic kidney disease. For instance, 14.5\u201316.2% of adults in the region reportedly have diabetes, versus 7.0% in Europe. Together with increasing life expectancy, this may contribute towards a higher burden of HFpEF in the region than currently reported. This paper aims to describe the epidemiology and burden of HFpEF in the MENAT region, including unique risk factors and co-morbidities. It highlights challenges with diagnosing HFpEF, such as the prioritization of HF with reduced ejection fraction (HFrEF), the specific profile of HFpEF patients in the region and barriers to effective management associated with the healthcare system. Guidance is given on the diagnosis, prevention and management of HFpEF, including the emerging role of sodium-glucose co-transporter-2 inhibitors. Given the high burden of HFpEF coupled with the fact that its prevalence is likely to be underestimated, healthcare professionals need to be alert to its signs and symptoms and to manage patients accordingly. Historically, HFpEF treatments have focused on managing co-morbidities and symptoms, but new agents are now available with proven effects on outcomes in patients with HFpEF.<\/jats:p>","DOI":"10.1002\/ehf2.14456","type":"journal-article","created":{"date-parts":[[2023,8,2]],"date-time":"2023-08-02T05:38:20Z","timestamp":1690954700000},"page":"2773-2787","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Regional Expert Opinion: Management of Heart Failure with Preserved Ejection Fraction in the Middle East, North Africa and Turkey"],"prefix":"10.1093","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6701-7072","authenticated-orcid":false,"given":"Magdy","family":"Abdelhamid","sequence":"first","affiliation":[{"name":"Faculty of Medicine, Cairo University , Cairo ,","place":["Egypt"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9896-5115","authenticated-orcid":false,"given":"Kamal","family":"Al Ghalayini","sequence":"additional","affiliation":[{"name":"King Abdulaziz University , Jeddah ,","place":["Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-0904-4164","authenticated-orcid":false,"given":"Khaldoon","family":"Al-Humood","sequence":"additional","affiliation":[{"name":"Chest Disease Hospital, Ministry of Health , Kuwait City ,","place":["Kuwait"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2687-8861","authenticated-orcid":false,"given":"B\u00fclent","family":"Altun","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Hacettepe University , Ankara ,","place":["Turkey"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6664-4584","authenticated-orcid":false,"given":"Mohammed","family":"Arafah","sequence":"additional","affiliation":[{"name":"Dallah Cardiac Centre, Dallah Hospital , Riyadh ,","place":["Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-6437-1167","authenticated-orcid":false,"given":"Feras","family":"Bader","sequence":"additional","affiliation":[{"name":"Cleveland Clinic , Abu Dhabi ,","place":["United Arab Emirates"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8307-2928","authenticated-orcid":false,"given":"Mohamed","family":"Ibrahim","sequence":"additional","affiliation":[{"name":"Boehringer Ingelheim IMETA , Dubai ,","place":["United Arab Emirates"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6960-1056","authenticated-orcid":false,"given":"Hani","family":"Sabbour","sequence":"additional","affiliation":[{"name":"Cleveland Clinic , Abu Dhabi ,","place":["United Arab Emirates"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3795-2422","authenticated-orcid":false,"given":"Ahmed","family":"Shawky Elserafy","sequence":"additional","affiliation":[{"name":"Ain Shams University , Cairo ,","place":["Egypt"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0541-4926","authenticated-orcid":false,"given":"Hadi","family":"Skouri","sequence":"additional","affiliation":[{"name":"Sheikh Shakhbout Medical City , Abu Dhabi ,","place":["United Arab Emirates"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8169-8628","authenticated-orcid":false,"given":"Mehmet Birhan","family":"Yilmaz","sequence":"additional","affiliation":[{"name":"Dokuz Eylul University , Izmir ,","place":["Turkey"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,8,2]]},"reference":[{"key":"2026012113212124500_ehf214456-bib-0001","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1002\/ejhf.1858","article-title":"Epidemiology of heart failure","volume":"22","author":"Groenewegen","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026012113212124500_ehf214456-bib-0002","first-page":"329","article-title":"Management of chronic heart failure in the older population","volume":"11","author":"Azad","year":"2014","journal-title":"J Geriatr Cardiol"},{"key":"2026012113212124500_ehf214456-bib-0003","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.ijcard.2011.02.025","article-title":"Clinical profile and predictors of in-hospital outcome in patients with heart failure: the FADOI \"CONFINE\" study","volume":"152","author":"Biagi","year":"2011","journal-title":"Int J Cardiol"},{"key":"2026012113212124500_ehf214456-bib-0004","volume-title":"GBD Compare","author":"Vizhub","year":"2023"},{"key":"2026012113212124500_ehf214456-bib-0005","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.122.027852","article-title":"Burden, trends, and inequalities of heart failure globally, 1990 to 2019: a secondary analysis based on the Global Burden of Disease 2019 study","volume":"12","author":"Yan","year":"2023","journal-title":"J Am Heart Assoc"},{"key":"2026012113212124500_ehf214456-bib-0006","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/s41569-021-00605-5","article-title":"Heart failure with mid-range or mildly reduced ejection fraction","volume":"19","author":"Savarese","year":"2022","journal-title":"Nat Rev Cardiol"},{"key":"2026012113212124500_ehf214456-bib-0007","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/nrcardio.2017.65","article-title":"Epidemiology of heart failure with preserved ejection fraction","volume":"14","author":"Dunlay","year":"2017","journal-title":"Nat Rev Cardiol"},{"key":"2026012113212124500_ehf214456-bib-0008","doi-asserted-by":"crossref","first-page":"236","DOI":"10.37616\/2212-5043.1040","article-title":"Heart failure in the Middle East Arab countries: current and future perspectives","volume":"32","author":"Elasfar","year":"2020","journal-title":"J Saudi Heart Assoc"},{"key":"2026012113212124500_ehf214456-bib-0009","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1016\/j.amjcard.2011.06.044","article-title":"Prevalence of heart failure with preserved ejection fraction in Latin American, Middle Eastern, and North African regions in the I PREFER study (Identification of Patients With Heart Failure and PREserved Systolic Function: an epidemiological regional study)","volume":"108","author":"Maga\u00f1a-Serrano","year":"2011","journal-title":"Am J Cardiol"},{"key":"2026012113212124500_ehf214456-bib-0010","doi-asserted-by":"crossref","first-page":"266","DOI":"10.18621\/eurj.1049360","article-title":"Baseline characteristics of outpatients with heart failure according to phenotype: preliminary analysis from SMYRNA-HF registry","volume":"8","author":"\u015eent\u00fcrk","year":"2022","journal-title":"Eur Respir J"},{"key":"2026012113212124500_ehf214456-bib-0011","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1002\/ejhf.57","article-title":"Clinical features, management, and short- and long-term outcomes of patients with acute decompensated heart failure: phase I results of the HEARTS database","volume":"16","author":"AlHabib","year":"2014","journal-title":"Eur J Heart Fail"},{"key":"2026012113212124500_ehf214456-bib-0012","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1002\/ejhf.245","article-title":"Clinical characteristics, management, and outcomes of acute heart failure patients: observations from the Gulf acute heart failure registry (Gulf CARE)","volume":"17","author":"Sulaiman","year":"2015","journal-title":"Eur J Heart Fail"},{"key":"2026012113212124500_ehf214456-bib-0013","doi-asserted-by":"crossref","first-page":"e665","DOI":"10.1016\/S2214-109X(17)30196-1","article-title":"Global mortality variations in patients with heart failure: results from the International Congestive Heart Failure (INTER-CHF) prospective cohort study","volume":"5","author":"Dokainish","year":"2017","journal-title":"Lancet Glob Health"},{"key":"2026012113212124500_ehf214456-bib-0014","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1093\/eurjhf\/hfp151","article-title":"Heart failure in patients hospitalized with acute coronary syndromes: observations from the Gulf Registry of Acute Coronary Events (Gulf RACE)","volume":"11","author":"Alsheikh-Ali","year":"2009","journal-title":"Eur J Heart Fail"},{"key":"2026012113212124500_ehf214456-bib-0015","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s43044-020-00082-0","article-title":"Demographics, clinical characteristics, and outcomes among hospitalized heart failure patients across different regions of Egypt","volume":"72","author":"Hassanin","year":"2020","journal-title":"Egypt Heart J"},{"key":"2026012113212124500_ehf214456-bib-0016","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1093\/eurjhf\/hfr111","article-title":"Design and preliminary results of the Heart Function Assessment Registry Trial in Saudi Arabia (HEARTS) in patients with acute and chronic heart failure","volume":"13","author":"AlHabib","year":"2011","journal-title":"Eur J Heart Fail"},{"key":"2026012113212124500_ehf214456-bib-0017","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1002\/ejhf.1492","article-title":"Acute heart failure congestion and perfusion status - impact of the clinical classification on in-hospital and long-term outcomes; insights from the ESC-EORP-HFA heart failure long-term registry","volume":"21","author":"Chioncel","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2026012113212124500_ehf214456-bib-0018","article-title":"Clinical characteristic and in-patients mortality among 100 patients with heart failure admitted to Ibn Seena central hospital, Mukalla, Hadhramout-Yemen. Iraqi","volume":"8","author":"Bahaj","year":"2010","journal-title":"J Med Sci"},{"key":"2026012113212124500_ehf214456-bib-0019","doi-asserted-by":"crossref","DOI":"10.1016\/j.jval.2018.04.840","article-title":"Understanding heart failure burden in Middle East countries: economic impact in Egypt, Saudi Arabia and United Arab Emirates","volume":"21","author":"AlHabeeb","year":"2018","journal-title":"Value Health"},{"key":"2026012113212124500_ehf214456-bib-0020","doi-asserted-by":"crossref","first-page":"48","DOI":"10.21608\/ejcm.2019.28131","article-title":"Cost-analysis of heart failure cases: a pilot single center study in Egypt","volume":"37","author":"Elrabbat","year":"2019","journal-title":"Egypt J Commun Med"},{"key":"2026012113212124500_ehf214456-bib-0021","doi-asserted-by":"crossref","first-page":"554","DOI":"10.14744\/AnatolJCardiol.2016.6999","article-title":"Cost of heart failure management in Turkey: results of a Delphi panel","volume":"16","author":"Aras","year":"2016","journal-title":"Anatol J Cardiol"},{"key":"2026012113212124500_ehf214456-bib-0022","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/s11897-013-0155-7","article-title":"The emerging epidemic of heart failure with preserved ejection fraction","volume":"10","author":"Oktay","year":"2013","journal-title":"Curr Heart Fail Rep"},{"key":"2026012113212124500_ehf214456-bib-0023","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s43044-023-00342-9","article-title":"The predictive value of precipitating factors on clinical outcomes in hospitalized patients with decompensated heart failure: insights from the Egyptian cohort in the European Society of Cardiology Heart Failure long-term registry","volume":"75","author":"Bendary","year":"2023","journal-title":"Egypt Heart J"},{"key":"2026012113212124500_ehf214456-bib-0024","article-title":"Comparison of demographics and outcomes of acute heart failure patients with reduced, mid-range, and preserved ejection fraction","volume":"2","author":"al-Jarallah","year":"2020","journal-title":"Ann Clin Cardiol"},{"key":"2026012113212124500_ehf214456-bib-0025","doi-asserted-by":"crossref","first-page":"263","DOI":"10.37616\/2212-5043.1025","article-title":"The prognostic impact of pulse pressure in acute heart failure: insights from the HEARTS registry","volume":"32","author":"Aljohar","year":"2020","journal-title":"J Saudi Heart Assoc"},{"key":"2026012113212124500_ehf214456-bib-0026","first-page":"234","article-title":"Comparison of clinical characteristics of patients with heart failure and preserved ejection fraction with atrial fibrillation versus sinus rhythm: insights from the APOLLON registry","volume":"48","author":"\u00d6zlek","year":"2020","journal-title":"Turk Kardiyol Dern Ars"},{"key":"2026012113212124500_ehf214456-bib-0027","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s43044-019-0032-0","article-title":"Clinical characteristics and in-hospital outcome of heart failure in women: a single center registry from Egyptian cardiac care unit","volume":"71","author":"Badran","year":"2019","journal-title":"Egypt Heart J"},{"key":"2026012113212124500_ehf214456-bib-0028","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0251658","article-title":"Epidemiology of heart failure and long-term follow-up outcomes in a north-African population: results from the NAtional TUnisian REgistry of heart failure (NATURE-HF)","volume":"16","author":"Abid","year":"2021","journal-title":"PLoS ONE"},{"key":"2026012113212124500_ehf214456-bib-0029","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.1016\/j.amjmed.2016.02.007","article-title":"Characteristics of hospitalizations for heart failure with preserved ejection fraction","volume":"129","author":"Goyal","year":"2016","journal-title":"Am J Med"},{"key":"2026012113212124500_ehf214456-bib-0030","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1002\/clc.23269","article-title":"Patients report more severe daily limitations than recognized by their physicians","volume":"42","author":"Castro","year":"2019","journal-title":"Clin Cardiol"},{"key":"2026012113212124500_ehf214456-bib-0031","doi-asserted-by":"crossref","DOI":"10.5001\/omj.2020.17","article-title":"Mortality and morbidity in HFrEF, HFmrEF, and HFpEF patients with diabetes in the Middle East","volume":"35","author":"al-Jarallah","year":"2020","journal-title":"Oman Med J"},{"key":"2026012113212124500_ehf214456-bib-0032","first-page":"297","article-title":"Impact of diabetes on mortality and rehospitalization in acute heart failure patients stratified by ejection fraction","volume":"7","author":"al-Jarallah","year":"2020","journal-title":"ESC Heart Fail"},{"key":"2026012113212124500_ehf214456-bib-0033","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jcmg.2017.08.007","article-title":"Epidemiology of left ventricular systolic dysfunction and heart failure in the Framingham study: an echocardiographic study over 3 decades","volume":"11","author":"Vasan","year":"2018","journal-title":"JACC Cardiovasc Imaging"},{"key":"2026012113212124500_ehf214456-bib-0034","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"key":"2026012113212124500_ehf214456-bib-0035","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ehj.2016.08.002","article-title":"Baseline characteristics of patients with heart failure and preserved ejection fraction at admission with acute heart failure in Saudi Arabia","volume":"69","author":"Abohammar","year":"2017","journal-title":"Egypt Heart J"},{"key":"2026012113212124500_ehf214456-bib-0036","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1002\/ejhf.51","article-title":"Hospitalized heart failure patients with preserved vs. reduced ejection fraction in Dubai, United Arab Emirates: a prospective study","volume":"16","author":"Saheb Sharif-Askari","year":"2014","journal-title":"Eur J Heart Fail"},{"key":"2026012113212124500_ehf214456-bib-0037","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1002\/ehf2.12347","article-title":"Gender differences in Egyptian patients hospitalized with heart failure: insights from the European Society of Cardiology Heart Failure Long-Term Registry","volume":"5","author":"Hassanein","year":"2018","journal-title":"ESC Heart Failure"},{"key":"2026012113212124500_ehf214456-bib-0038","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.ejim.2018.11.001","article-title":"Patients with HFpEF and HFmrEF have different clinical characteristics in Turkey: a multicenter observational study","volume":"61","author":"\u00d6zlek","year":"2019","journal-title":"Eur J Intern Med"},{"key":"2026012113212124500_ehf214456-bib-0039","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.hrtlng.2020.03.023","article-title":"Epidemiology and clinical characteristics of hospitalized elderly patients for heart failure with reduced, mid-range and preserved ejection fraction","volume":"49","author":"Gok","year":"2020","journal-title":"Heart Lung"},{"key":"2026012113212124500_ehf214456-bib-0040","volume-title":"IDF Diabetes Atlas, 10th Edition","author":"International Diabetes Federation","year":"2022"},{"key":"2026012113212124500_ehf214456-bib-0041","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2022\/8074837","article-title":"Prevalence of obesity and overweight among adults in the Middle East countries from 2000 to 2020: a systematic review and meta-analysis","volume":"2022","author":"Okati-Aliabad","year":"2022","journal-title":"J Obes"},{"key":"2026012113212124500_ehf214456-bib-0042","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1038\/s41371-021-00647-9","article-title":"Prevalence of hypertension and pre-hypertension in the Middle East region: a systematic review & meta-analysis","volume":"36","author":"Okati-Aliabad","year":"2022","journal-title":"J Hum Hypertens"},{"key":"2026012113212124500_ehf214456-bib-0043","doi-asserted-by":"crossref","first-page":"67","DOI":"10.4103\/2230-8210.91193","article-title":"Metabolic syndrome in the Middle East","volume":"16","author":"Sliem","year":"2012","journal-title":"Ind J Endocrinol Metab"},{"key":"2026012113212124500_ehf214456-bib-0044","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1186\/s12933-018-0787-8","article-title":"Vascular complications in patients with type 2 diabetes: prevalence and associated factors in 38 countries (the DISCOVER study program)","volume":"17","author":"Kosiborod","year":"2018","journal-title":"Cardiovasc Diabetol"},{"key":"2026012113212124500_ehf214456-bib-0045","first-page":"824","article-title":"Obesity in Saudi Arabia","volume":"26","author":"al-Nozha","year":"2005","journal-title":"Saudi Med J"},{"key":"2026012113212124500_ehf214456-bib-0046","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1093\/eurheartj\/ehab892","article-title":"European Society of Cardiology: cardiovascular disease statistics 2021","volume":"43","author":"Timmis","year":"2022","journal-title":"Eur Heart J"},{"key":"2026012113212124500_ehf214456-bib-0047","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1093\/eurheartj\/ehz859","article-title":"European Society of Cardiology: cardiovascular disease statistics 2019","volume":"41","author":"Timmis","year":"2020","journal-title":"Eur Heart J"},{"key":"2026012113212124500_ehf214456-bib-0048","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1007\/s00125-014-3171-6","article-title":"Molecular mechanisms of diabetic cardiomyopathy","volume":"57","author":"Bugger","year":"2014","journal-title":"Diabetologia"},{"key":"2026012113212124500_ehf214456-bib-0049","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/s41371-020-00480-6","article-title":"Profile of hypertension in Turkey: from prevalence to patient awareness and compliance with therapy, and a focus on reasons of increase in hypertension among youths","volume":"36","author":"Pamukcu","year":"2022","journal-title":"J Hum Hypertens"},{"key":"2026012113212124500_ehf214456-bib-0050","article-title":"Estimating the prevalence and awareness rates of hypertension in Africa: a systematic analysis","volume":"9","author":"Adeloye","year":"2014","journal-title":"PLoS ONE"},{"key":"2026012113212124500_ehf214456-bib-0051","volume-title":"Prevalence of tobacco smoking","author":"World Health Organization","year":"2022"},{"key":"2026012113212124500_ehf214456-bib-0052","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1161\/CIRCULATIONAHA.119.037606","article-title":"Control and management of cardiovascular disease in Turkey","volume":"141","author":"Kayikcioglu","year":"2020","journal-title":"Circulation"},{"key":"2026012113212124500_ehf214456-bib-0053","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1186\/s13045-021-01202-2","article-title":"Burden of anemia and its underlying causes in 204 countries and territories, 1990\u20132019: results from the Global Burden of Disease study 2019","volume":"14","author":"Safiri","year":"2021","journal-title":"J Hematol Oncol"},{"key":"2026012113212124500_ehf214456-bib-0054","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1186\/s12931-022-02242-z","article-title":"The burden of chronic obstructive pulmonary disease and its attributable risk factors in the Middle East and North Africa region, 1990\u20132019","volume":"23","author":"Feizi","year":"2022","journal-title":"Respir Res"},{"key":"2026012113212124500_ehf214456-bib-0055","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2021-069679","article-title":"Burden of chronic obstructive pulmonary disease and its attributable risk factors in 204 countries and territories, 1990-2019: results from the Global Burden of Disease study 2019","volume":"378","author":"Safiri","year":"2022","journal-title":"BMJ"},{"key":"2026012113212124500_ehf214456-bib-0056","doi-asserted-by":"crossref","DOI":"10.3389\/fpubh.2022.1015902","article-title":"Regional burden of chronic kidney disease in North Africa and Middle East during 1990-2019; results from Global Burden of Disease study 2019","volume":"10","author":"Tabatabaei-Malazy","year":"2022","journal-title":"Front Public Health"},{"key":"2026012113212124500_ehf214456-bib-0057","volume-title":"Chronic kidney disease\u2014Level 3 cause","author":"The Lancet","year":"2019"},{"key":"2026012113212124500_ehf214456-bib-0058","doi-asserted-by":"crossref","first-page":"3297","DOI":"10.1093\/eurheartj\/ehz641","article-title":"How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC)","volume":"40","author":"Pieske","year":"2019","journal-title":"Eur Heart J"},{"key":"2026012113212124500_ehf214456-bib-0059","doi-asserted-by":"crossref","first-page":"e880","DOI":"10.3399\/bjgp20X713477","article-title":"Understanding the management of heart failure with preserved ejection fraction: a qualitative multiperspective study","volume":"70","author":"Sowden","year":"2020","journal-title":"Br J Gen Pract"},{"key":"2026012113212124500_ehf214456-bib-0060","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/j.amjcard.2012.05.014","article-title":"Prevalence, clinical phenotype, and outcomes associated with normal B-type natriuretic peptide levels in heart failure with preserved ejection fraction","volume":"110","author":"Anjan","year":"2012","journal-title":"Am J Cardiol"},{"key":"2026012113212124500_ehf214456-bib-0061","first-page":"e895","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association joint committee on clinical practice guidelines","volume":"145","author":"Heidenreich","year":"2022","journal-title":"Circulation"},{"key":"2026012113212124500_ehf214456-bib-0062","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1002\/ehf2.12046","article-title":"Clinical characteristics and management of hospitalized and ambulatory patients with heart failure-results from ESC heart failure long-term registry-Egyptian cohort","volume":"2","author":"Hassanein","year":"2015","journal-title":"ESC Heart Fail"},{"key":"2026012113212124500_ehf214456-bib-0063","doi-asserted-by":"crossref","first-page":"174","DOI":"10.2174\/1573403X11309020009","article-title":"Heart failure in the Middle East","volume":"9","author":"Al-Shamiri","year":"2013","journal-title":"Curr Cardiol Rev"},{"key":"2026012113212124500_ehf214456-bib-0064","doi-asserted-by":"crossref","first-page":"115","DOI":"10.5830\/CVJA-2018-027","article-title":"Status of cardiac arrhythmia services in Africa in 2018: a PASCAR sudden cardiac death task force report","volume":"29","author":"Talle","year":"2018","journal-title":"Cardiovasc J Afr"},{"key":"2026012113212124500_ehf214456-bib-0065","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s43044-019-0024-0","article-title":"Preliminary results of the acute heart failure registry in the DELTA region of Egypt (DELTA-HF): a database and a quality initiative project","volume":"71","author":"Elasfar","year":"2019","journal-title":"Egypt Heart J"},{"key":"2026012113212124500_ehf214456-bib-0066","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1161\/CIRCULATIONAHA.118.034646","article-title":"A simple, evidence-based approach to help guide diagnosis of heart failure with preserved ejection fraction","volume":"138","author":"Reddy","year":"2018","journal-title":"Circulation"},{"key":"2026012113212124500_ehf214456-bib-0067","first-page":"666","article-title":"Prognosis of heart failure with preserved ejection fraction in primary care by the H2FPEF score","volume":"33","author":"Jorge","year":"2020","journal-title":"Int J Cardiovasc Sci"},{"key":"2026012113212124500_ehf214456-bib-0068","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.2337\/dci22-0014","article-title":"Heart failure: an underappreciated complication of diabetes. A consensus report of the American Diabetes Association","volume":"45","author":"Pop-Busui","year":"2022","journal-title":"Diabetes Care"},{"key":"2026012113212124500_ehf214456-bib-0069","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1136\/heartjnl-2020-318060","article-title":"Sodium-glucose co-transporter 2 inhibitor therapy: mechanisms of action in heart failure","volume":"107","author":"Joshi","year":"2021","journal-title":"Heart"},{"key":"2026012113212124500_ehf214456-bib-0070","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1007\/s13300-022-01272-6","article-title":"Characteristics and treatment patterns of patients with type 2 diabetes mellitus in the Middle East and Africa cohort of the DISCOVER study program: a prospective study","volume":"13","author":"al-Rubeaan","year":"2022","journal-title":"Diabetes Ther"},{"key":"2026012113212124500_ehf214456-bib-0071","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1161\/CIRCULATIONAHA.123.064345","article-title":"Prevalence of diabetes and cardiovascular risk in the Middle East and Africa: primary results of the PACT-MEA study","volume":"147","author":"Verma","year":"2023","journal-title":"Circulation"},{"key":"2026012113212124500_ehf214456-bib-0072","doi-asserted-by":"crossref","first-page":"706","DOI":"10.2337\/dc16-1943","article-title":"Sulfonylureas and the risks of cardiovascular events and death: a methodological meta-regression analysis of the observational studies","volume":"40","author":"Azoulay","year":"2017","journal-title":"Diabetes Care"},{"key":"2026012113212124500_ehf214456-bib-0073","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/s43044-021-00218-w","article-title":"SGLT2 inhibitors in heart failure with reduced ejection fraction","volume":"73","author":"Das","year":"2021","journal-title":"Egypt Heart J"},{"key":"2026012113212124500_ehf214456-bib-0074","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"2026012113212124500_ehf214456-bib-0075","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N Engl J Med"},{"key":"2026012113212124500_ehf214456-bib-0076","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"key":"2026012113212124500_ehf214456-bib-0077","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMoa2004967","article-title":"Cardiovascular outcomes with ertugliflozin in type 2 diabetes","volume":"383","author":"Cannon","year":"2020","journal-title":"N Engl J Med"},{"key":"2026012113212124500_ehf214456-bib-0078","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1093\/eurheartj\/ehl250","article-title":"The Perindopril in Elderly People with Chronic Heart Failure (PEP-CHF) study","volume":"27","author":"Cleland","year":"2006","journal-title":"Eur Heart J"},{"key":"2026012113212124500_ehf214456-bib-0079","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/S0140-6736(03)14285-7","article-title":"Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-preserved trial","volume":"362","author":"Yusuf","year":"2003","journal-title":"Lancet"},{"key":"2026012113212124500_ehf214456-bib-0080","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1056\/NEJMoa0805450","article-title":"Irbesartan in patients with heart failure and preserved ejection fraction","volume":"359","author":"Massie","year":"2008","journal-title":"N Engl J Med"},{"key":"2026012113212124500_ehf214456-bib-0081","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa1313731","article-title":"Spironolactone for heart failure with preserved ejection fraction","volume":"370","author":"Pitt","year":"2014","journal-title":"N Engl J Med"},{"key":"2026012113212124500_ehf214456-bib-0082","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1161\/CIRCULATIONAHA.106.628347","article-title":"Effects of digoxin on morbidity and mortality in diastolic heart failure: the ancillary digitalis investigation group trial","volume":"114","author":"Ahmed","year":"2006","journal-title":"Circulation"},{"key":"2026012113212124500_ehf214456-bib-0083","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1056\/NEJMoa1908655","article-title":"Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction","volume":"381","author":"Solomon","year":"2019","journal-title":"N Engl J Med"},{"key":"2026012113212124500_ehf214456-bib-0084","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1093\/eurheartj\/ehv464","article-title":"Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction","volume":"37","author":"Solomon","year":"2016","journal-title":"Eur Heart J"},{"key":"2026012113212124500_ehf214456-bib-0085","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s10741-006-9488-6","article-title":"The treatment of heart failure with preserved ejection fraction (\"diastolic heart failure\")","volume":"11","author":"Hogg","year":"2006","journal-title":"Heart Fail Rev"},{"key":"2026012113212124500_ehf214456-bib-0086","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1161\/CIRCULATIONAHA.119.044586","article-title":"Sacubitril\/valsartan across the spectrum of ejection fraction in heart failure","volume":"141","author":"Solomon","year":"2020","journal-title":"Circulation"},{"key":"2026012113212124500_ehf214456-bib-0087","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N Engl J Med"},{"key":"2026012113212124500_ehf214456-bib-0088","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"key":"2026012113212124500_ehf214456-bib-0089","volume-title":"US FDA approves Jardiance\u00ae (empagliflozin) to treat adults living with heart failure with reduced ejection fraction.","author":"Boehringer Ingelheim","year":"2022"},{"key":"2026012113212124500_ehf214456-bib-0090","volume-title":"FDA approves new treatment for a type of heart failure","author":"U. S. Food & Drug Administration","year":"2021"},{"key":"2026012113212124500_ehf214456-bib-0091","volume-title":"Summary of opinion (post authorisation) Jardince empagliflozin","author":"European Medicines Agency","year":"2021"},{"key":"2026012113212124500_ehf214456-bib-0092","volume-title":"Summary of opinion (post authorisation) Forxiga dapagliflozin","author":"European Medicines Agency","year":"2023"},{"key":"2026012113212124500_ehf214456-bib-0093","volume-title":"Farxiga extended in the US to reduce risk of cardiovascular death and hospitalisation for heart failure to a broader range of patients","author":"AstraZeneca"},{"key":"2026012113212124500_ehf214456-bib-0094","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N Engl J Med"},{"key":"2026012113212124500_ehf214456-bib-0095","volume-title":"Summary of opinion (post authorisation) Jardiance empagliflozin","author":"European Medicines Agency","year":"2022"},{"key":"2026012113212124500_ehf214456-bib-0096","volume-title":"FDA approves treatment for wider range of patients with heart failure","author":"U. S. Food & Drug Administration","year":"2022"},{"key":"2026012113212124500_ehf214456-bib-0097","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.118.004962","article-title":"Baseline characteristics of patients with heart failure and preserved ejection fraction in the PARAGON-HF trial","volume":"11","author":"Solomon","year":"2018","journal-title":"Circ Heart Fail"},{"key":"2026012113212124500_ehf214456-bib-0098","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1002\/ejhf.2064","article-title":"Baseline characteristics of patients with heart failure with preserved ejection fraction in the EMPEROR-preserved trial","volume":"22","author":"Anker","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026012113212124500_ehf214456-bib-0099","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1002\/ejhf.1596","article-title":"Evaluation of the effects of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality in patients with chronic heart failure and a preserved ejection fraction: rationale for and design of the EMPEROR-preserved trial","volume":"21","author":"Anker","year":"2019","journal-title":"Eur J Heart Fail"},{"issue":"1","key":"2026012113212124500_ehf214456-bib-0100","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jacc.2022.04.040","article-title":"Empagliflozin improves outcomes in patients with heart failure and preserved ejection fraction irrespective of age","volume":"80","author":"B\u00f6hm","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"2026012113212124500_ehf214456-bib-0101","doi-asserted-by":"crossref","DOI":"10.1002\/ejhf.2861","article-title":"Empagliflozin in heart failure with preserved ejection fraction with and without atrial fibrillation","author":"Fillippatos","year":"2023","journal-title":"Eur J Heart Fail."},{"key":"2026012113212124500_ehf214456-bib-0102","volume-title":"European Society of Cardiology Heart Failure","author":"Sattar","year":"2022"},{"issue":"5","key":"2026012113212124500_ehf214456-bib-0103","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1093\/eurheartj\/ehac693","article-title":"Empagliflozin, irrespective of blood pressure, improves outcomes in heart failure with preserved ejection fraction: the EMPEROR-Preserved trial","volume":"44","author":"B\u00f6hm","year":"2022","journal-title":"Eur Heart J"},{"key":"2026012113212124500_ehf214456-bib-0104","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction","volume":"387","author":"Solomon","year":"2022","journal-title":"N Engl J Med"},{"key":"2026012113212124500_ehf214456-bib-0105","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1002\/ejhf.2249","article-title":"Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the DELIVER trial","volume":"23","author":"Solomon","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026012113212124500_ehf214456-bib-0106","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1002\/ejhf.2558","article-title":"Outcomes with empagliflozin in heart failure with preserved ejection fraction using DELIVER-like endpoint definitions","volume":"24","author":"Anker","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"2026012113212124500_ehf214456-bib-0107","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.ijcard.2015.11.183","article-title":"Heart failure in Africa, Asia, the Middle East and South America: the INTER-CHF study","volume":"204","author":"Dokainish","year":"2016","journal-title":"Int J Cardiol"},{"key":"2026012113212124500_ehf214456-bib-0108","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.ijcard.2017.02.087","article-title":"Clinical characteristics, management and outcomes of patients with chronic heart failure: results from the Heart Function Assessment Registry Trial in Saudi Arabia (HEARTS-chronic)","volume":"235","author":"Alhabeeb","year":"2017","journal-title":"Int J Cardiol"},{"key":"2026012113212124500_ehf214456-bib-0109","first-page":"557","article-title":"Patient medication adherence and physician prescribing among congestive heart failure patients of Yemen","volume":"75","author":"Alakhali","year":"2013","journal-title":"Indian J Pharm Sci"},{"key":"2026012113212124500_ehf214456-bib-0110","first-page":"e191","article-title":"Medication adherence and health literacy in patients with heart failure: a cross-sectional survey in Iran","volume":"6","author":"Rezaei","year":"2022","journal-title":"Health Lit Res Pract"},{"key":"2026012113212124500_ehf214456-bib-0111","doi-asserted-by":"crossref","first-page":"81","DOI":"10.4103\/nms.nms_9_17","article-title":"Medication adherence and its predictors among patients with heart failure","volume":"7","author":"Amininasab","year":"2018","journal-title":"Nurs Midwifery Stud"},{"key":"2026012113212124500_ehf214456-bib-0112","article-title":"Predictive factors of medication adherence in patients with chronic heart failure: Morocco's experience","volume":"26","author":"Ragbaoui","year":"2017","journal-title":"Pan Afr Med J"},{"key":"2026012113212124500_ehf214456-bib-0113","doi-asserted-by":"crossref","DOI":"10.5812\/jjcdc.68310","article-title":"Determinants of medication adherence among Iranian elderly patients with chronic diseases","volume":"7","author":"Taheri Kharameh","year":"2018","journal-title":"Jundishapur J Chronic Dis Care"},{"key":"2026012113212124500_ehf214456-bib-0114","doi-asserted-by":"crossref","first-page":"5041","DOI":"10.4103\/jfmpc.jfmpc_904_20","article-title":"Adherence of heart failure patients to heart failure medications and its determinants in the Aseer region, southern Saudi Arabia","volume":"9","author":"Raffaa","year":"2020","journal-title":"J Family Med Prim Care"},{"key":"2026012113212124500_ehf214456-bib-0115","doi-asserted-by":"crossref","first-page":"828","DOI":"10.26719\/emhj.19.017","article-title":"Health literacy among Iranian adults: findings from a nationwide population-based survey in 2015","volume":"25","author":"Haghdoost","year":"2019","journal-title":"East Mediterr Health J"},{"key":"2026012113212124500_ehf214456-bib-0116","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/s41591-021-01659-1","article-title":"The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial","volume":"28","author":"Voors","year":"2022","journal-title":"Nat Med"},{"key":"2026012113212124500_ehf214456-bib-0117","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.3389\/fphys.2019.01108","article-title":"Chronic kidney disease as a risk factor for heart failure with preserved ejection fraction: a focus on microcirculatory factors and therapeutic targets","volume":"10","author":"van de Wouw","year":"2019","journal-title":"Front Physiol"},{"key":"2026012113212124500_ehf214456-bib-0118","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1093\/eurheartj\/ehp507","article-title":"Cardio-renal syndromes: report from the consensus conference of the acute dialysis quality initiative","volume":"31","author":"Ronco","year":"2010","journal-title":"Eur Heart J"},{"key":"2026012113212124500_ehf214456-bib-0119","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1002\/ejhf.2471","article-title":"Renal effects of guideline-directed medical therapies in heart failure: a consensus document from the Heart Failure Association of the European Society of Cardiology","volume":"24","author":"Mullens","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"2026012113212124500_ehf214456-bib-0120","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1136\/heartjnl-2018-314158","article-title":"Change in renal function associated with drug treatment in heart failure: national guidance","volume":"105","author":"Clark","year":"2019","journal-title":"Heart"},{"key":"2026012113212124500_ehf214456-bib-0121","doi-asserted-by":"crossref","DOI":"10.1002\/ejhf.2857","article-title":"Cardiac and kidney benefits of empagliflozin in heart failure across the spectrum of kidney function: insights from the EMPEROR-Preserved trial","author":"Sharma","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"2026012113212124500_ehf214456-bib-0122","volume-title":"EMPEROR-preserved: empagliflozin and outcomes in heart failure with a preserved ejection fraction and CKD","author":"Zannad","year":"2021"},{"key":"2026012113212124500_ehf214456-bib-0123","doi-asserted-by":"crossref","first-page":"e137","DOI":"10.1161\/CIR.0000000000000509","article-title":"2017 ACC\/AHA\/HFSA focused update of the 2013 ACCF\/AHA guideline for the Management of Heart Failure: a report of the American College of Cardiology\/American Heart Association task force on clinical practice guidelines and the Heart Failure Society of America","volume":"136","author":"Yancy","year":"2017","journal-title":"Circulation"},{"key":"2026012113212124500_ehf214456-bib-0124","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1002\/ehf2.13811","article-title":"Egyptian expert opinion for the use of sodium-glucose cotransporter-2 inhibitors in patients with heart failure with reduced ejection fraction","volume":"9","author":"Abdelhamid","year":"2022","journal-title":"ESC Heart Fail"}],"container-title":["ESC Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/10\/5\/2773\/66227846\/eschf_10_5_2773.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/10\/5\/2773\/66227846\/eschf_10_5_2773.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T18:26:26Z","timestamp":1769019986000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eschf\/article\/10\/5\/2773\/8284402"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,2]]},"references-count":124,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2023,8,2]]},"published-print":{"date-parts":[[2023,10,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ehf2.14456","relation":{},"ISSN":["2055-5822"],"issn-type":[{"value":"2055-5822","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,10]]},"published":{"date-parts":[[2023,8,2]]},"assertion":[{"value":"2023-02-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-06-21","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-08-02","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}